Roderick P, Davies R, Raftery J, Crabbe D, Pearce R, Patel P, Bhandari P
Health Care Research Unit, University of Southampton, Southampton.
J Med Screen. 2003;10(3):148-56. doi: 10.1177/096914130301000310.
To evaluate the cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease in England and Wales.
A discrete event simulation model used parameter estimates, derived from peer-reviewed literature, routine data and statistical modelling. Population screening was compared with no screening but with opportunistic eradication in patients presenting with dyspepsia. Costs included screening, eradication and costs averted to provide costs per life years saved (cost/LYS) for preventing gastric cancer and peptic ulcer disease. Sensitivity analyses were undertaken.
The cost/LYS from screening at age 40 years was Uk pounds 5860 at discount rates of 6%. The outcomes were sensitive to H. pylori prevalence, the degree of opportunistic eradication, the discount rate, the efficacy of eradication on gastric cancer risk, the risk of complicated peptic ulcer disease and gastric cancer associated with H. pylori infection, and the duration of follow-up. In sensitivity analyses, the cost/LYS rarely exceeded UK pounds 20000 over an 80-year follow-up, but did for shorter periods.
H. pylori screening may be cost-effective in the long term. However, before screening can be recommended further evidence is needed to resolve some of the uncertainties, particularly over the efficacy of eradication on risk of gastric cancer, the risk associated with complicated peptic ulcers, and the effect of more widespread opportunistic testing of patients with dyspepsia.
评估在英格兰和威尔士进行幽门螺杆菌人群筛查预防胃癌和消化性溃疡疾病的成本效益。
采用离散事件模拟模型,其参数估计来自同行评审文献、常规数据和统计建模。将人群筛查与不筛查但对消化不良患者进行机会性根除治疗进行比较。成本包括筛查、根除治疗以及避免的成本,以得出预防胃癌和消化性溃疡疾病每挽救一个生命年的成本(成本/生命年)。进行了敏感性分析。
40岁时进行筛查,在6%的贴现率下,成本/生命年为5860英镑。结果对幽门螺杆菌感染率、机会性根除治疗的程度、贴现率、根除治疗对胃癌风险的疗效、复杂消化性溃疡疾病和与幽门螺杆菌感染相关的胃癌风险以及随访持续时间敏感。在敏感性分析中,在80年的随访期内,成本/生命年很少超过20000英镑,但在较短时期内会超过。
从长期来看,幽门螺杆菌筛查可能具有成本效益。然而,在推荐进行筛查之前,需要更多证据来解决一些不确定性问题,特别是根除治疗对胃癌风险的疗效、与复杂消化性溃疡相关的风险以及对消化不良患者更广泛进行机会性检测的效果。